Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery

Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 313 Ferst Drive, Atlanta, Georgia 30332, USA.
Acta biomaterialia (Impact Factor: 6.03). 10/2013; 10(4). DOI: 10.1016/j.actbio.2013.09.039
Source: PubMed


Glycosaminoglycans (GAGs) are linear, negatively charged polysaccharides that interact with a variety of positively-charged growth factors. In this review article, the effects of engineering GAG chemistry for molecular delivery applications in regenerative medicine are presented. Three major areas of focus at the structure-function-property interface are discussed: 1) macromolecular properties of GAGs, 2) effects of chemical modifications on protein binding, and 3) degradation mechanisms of GAGs. GAG-protein interactions can be based on 1) GAG sulfation pattern, 2) GAG carbohydrate conformation, and 3) GAG polyelectrolyte behavior. Chemical modifications of GAGs, which are commonly performed to engineer molecular delivery systems, affect protein binding and are highly dependent on the site of modification on the GAG molecules. The rate and mode of degradation can determine the release of molecules as well as the length of GAG fragments to which the cargo is electrostatically coupled and eventually released from the delivery system. Overall, GAG-based polymers are a versatile biomaterial platform offering novel means to engineer molecular delivery systems with a high degree of control in order to better treat a range of degenerate or injured tissues.

Download full-text


Available from: Todd C. McDevitt,
  • Source
    • "The gelatin methacrylate microparticles used in this study were thermally cross-linked with free radical polymerization in a manner similar to heparin methacrylamide; since w55% of the amines on the gelatin methacrylate microparticles were substituted with methacrylate groups, a similar crosslinking density to heparin microparticles could be achieved (data unpublished). Although gelatin also primarily binds positively charged growth factors through electrostatic interactions, heparin microparticles captured and retained significantly more BMP-2 than gelatin microparticles, due to their higher charge density [10] [11]. Previous studies investigating the co-delivery of heparin and BMP-2 have demonstrated both stimulatory and inhibitory effects Fig. 4. Effect of heparin microparticles loaded with BMP-2 on alkaline phosphatase activity in C2C12 cultures. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Biomaterials capable of providing localized and sustained presentation of bioactive proteins are critical for effective therapeutic growth factor delivery. However, current biomaterial delivery vehicles commonly suffer from limitations that can result in low retention of growth factors at the site of interest or adversely affect growth factor bioactivity. Heparin, a highly sulfated glycosaminoglycan, is an attractive growth factor delivery vehicle due to its ability to reversibly bind positively charged proteins, provide sustained delivery, and maintain protein bioactivity. This study describes the fabrication and characterization of heparin methacrylamide (HMAm) microparticles for recombinant growth factor delivery. HMAm microparticles were shown to efficiently bind several heparin-binding growth factors (e.g. bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (FGF-2)), including a wide range of BMP-2 concentrations that exceeds the maximum binding capacity of other common growth factor delivery vehicles, such as gelatin. BMP-2 bioactivity was assessed on the basis of alkaline phosphatase (ALP) activity induced in skeletal myoblasts (C2C12). Microparticles loaded with BMP-2 stimulated comparable C2C12 ALP activity to soluble BMP-2 treatment, indicating that BMP-2-loaded microparticles retain bioactivity and potently elicit a functional cell response. In summary, our results suggest that heparin microparticles stably retain large amounts of bioactive BMP-2 for prolonged periods of time, and that presentation of BMP-2 via heparin microparticles can elicit cell responses comparable to soluble BMP-2 treatment. Consequently, heparin microparticles present an effective method of delivering and spatially retaining growth factors that could be used in a variety of systems to enable directed induction of cell fates and tissue regeneration.
    Biomaterials 05/2014; 35(25). DOI:10.1016/j.biomaterials.2014.05.011 · 8.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cell (MSC) therapies have the potential to treat many pathologies, however, controlling cell fate after implantation remains challenging. We have used a multilayer technology to graft a range of 5 μg mL−1–5 mg mL−1 heparin onto the surface of MSC aggregates. Heparin coating does not affect cell viability (seen through LIVE/DEAD staining) and cell anti-inflammatory properties (seen through co-culture with activated monocytes) and facilitates sequestration by coated cells of a growth factor (TGF-β1) that remains bioactive. This system can maximize the therapeutic potential of MSC-based treatments because the cell surfaceloaded protein could both signal the cells to influence transplanted cell fate and be released into the surrounding environment to help repair injured tissue.
    Biomaterials Science 03/2014; 2(5). DOI:10.1039/c3bm60271k · 3.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate the plasma keratan sulfate (KS) level as a potential marker of joint damage in children with juvenile idiopathic arthritis (JIA). The influence of growth factors as well as proteolytic and prooxidative agents on aggrecan alterations were evaluated in this study. Plasma levels of KS, transforming growth factor β1 (TGF-β1), platelet-derived growth factor BB (PDGF-BB), a disintegrin and metalloproteinase with thrombospondin motifs 4 and 5 (ADAMTS-4 and ADAMTS-5), and thiol groups (TG) were quantified in samples obtained from 30 healthy subjects and 30 patients with JIA before and after treatment. Increased (p
    Clinical Chemistry and Laboratory Medicine 08/2014; 53(2). DOI:10.1515/cclm-2014-0441 · 2.71 Impact Factor
Show more